Artificial intelligence is a great trend in caring for cancer and mainly focuses on detecting cancer at the earliest possible stage. This makes sense, considering that the cancer is less deadly, the previously it has been detected.
But less a basic query asks: does anyone have cancer, or is it mandatory aggressive treatment comparable to chemotherapy? This is a problem of Ataraxis AI is trying to resolve.
The New York startup focuses on the use of artificial intelligence to accurately predict not only if the patient has cancer, but also what his cancer result looks like for five to 10 years. If there is only a little likelihood to return cancer, you may completely avoid chemistry – save a lot of money, while avoiding the famous unwanted effects of treatment.
Ataraxis AI is now planning to conduct his first business test, for breast cancer, American oncologists in the coming months, said Techcrunch, his co -founder Jan (*20*). To strengthen the premiere and expand to other types of cancer, the startup collected $ 20.4 million of the A series, said only TechCrunch.
The round was run by AIX Ventures with the participation of Thiel Bio, Funders Fund, Floating Point, Bertelsmann and existing gigantic projects of investors and obvious projects. Ataraxis appeared From Stealth last yr with a round of $ 4 million.
Ataraxis was co -founded by (*20*) and Krzysztof Geras, an assistant to the professor at NYU’s Medical School, who focuses on artificial intelligence.
Techka Ataraxis is powered by the AI model, which extracts information from high -resolution cancer cell images. (*20*) said that the model is trained on tons of of tens of millions of real images from 1000’s of patients. The last study showed that Ataraxis technology was 30% more accurate than the current standard of breast cancer care for ataraxis.
Long -term Ataraxis has great ambitions. He wants his tests to affect at least half of the recent cases of cancer by 2030. The Frontier AI is also considered to be the company, which builds its own models, promoting the primary scientist AI Meta Yann Lecun as an AI adviser.
“I think that in Ataraxis we try to build what is essentially the AI border laboratory, but in the case of healthcare application,” said (*20*). “Because so many of these problems require very innovative technology.”
AI boom led to a rush to lift funds for startups for caring for cancer. Valar Labs collected $ 22 million to assist patients determine the treatment plan in May 2024. In the cancer space there is also a number of corporations to find AI powered drugs, comparable to Manas AI, which collected $ 24.6 million in January 2025 and was co -founded by Reid Hoffman, co -founder of LinkedIn.